decisionhealth Newsletters, Part B News - 2013 Issue 9 (September)
New RAC issue: Drug screening claims face audit scrutiny
Subscribe or sign in to view the full article.
Article Overview
This article covers a new RAC audit focus on urine drug screening claims, with attention to CMS guidance on reporting drug screen services in practice and laboratory settings. It is relevant to providers, billing staff, coders, and compliance teams who work with Medicare laboratory services and need to understand the general categories of policy and audit concerns discussed in the article.
Why This Topic Matters
The topic is important because urine drug screening billing is under audit scrutiny, and practices that bill these services need to recognize the broader CMS policy context referenced in the article.
Article Sections
-
New policy changes for drug tests
This section discusses recent CMS policy shifts and the audit environment affecting urine drug screening claims. It frames the article’s focus on Medicare billing scrutiny and related compliance concerns.
-
Make sure your providers abide by the following rules to keep from owing overpayments:
This section summarizes the CMS and RAC guidance referenced in the article for urine drug screening services, including laboratory coverage, reporting considerations, and related coding context.
What You Will Learn
- How a RAC audit initiative affects urine drug screening claims
- Which CMS policy sources are referenced for urine drug testing guidance
- What broad billing and compliance areas are discussed for practice and laboratory settings
- How the article frames concerns about multiple testing scenarios and audit risk
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Compliance professionals
- Pathology and laboratory staff
- Physician practice administrators
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com